Limited EvidencePeptide

DSIP

Delta Sleep-Inducing Peptide

Sleep-Associated Nonapeptide

Last updated: August 2026

Evidence Level: Limited Evidence

Mostly animal data or anecdotal reports, theoretical basis

Regulatory Status: Not approved anywhere. Listed by the FDA as emideltide and placed in 503A Category 2 in 2023. On July 23-24, 2026 it was the only peptide the FDA advisory committee voted against recommending for the 503A list, by 7 to 6 with one abstention.

DSIP is a nine-amino-acid peptide isolated from rabbit brain in 1977 during experiments on sleep induction. It got its name from what researchers hoped it did. Nearly fifty years later, human sleep studies remain small, inconsistent, and unreplicated, and in July 2026 it became the only peptide an FDA advisory panel voted against.

How It Works

The origin story explains a lot about why DSIP is still around.

In 1977, Swiss researchers electrically stimulated a brain region in rabbits to induce sleep, then took blood from those animals and isolated a peptide from it. They transferred that peptide into other animals and reported increased delta wave sleep, the deep slow-wave stage. They named it delta sleep-inducing peptide after the effect they were looking for.

That is a genuinely interesting experiment. The problem is that the name became the claim, and the claim has outlived the evidence supporting it for almost half a century.

What the mechanism is supposed to be. DSIP is described as modulating several systems: influencing the hypothalamic-pituitary-adrenal axis and cortisol rhythm, interacting with opioid and GABA systems, and having some antioxidant activity. Beyond that, there is no clear, agreed receptor. That is unusual for a peptide that has been studied for this long, and it is part of why the FDA has struggled to evaluate it.

What human studies actually found. Human sleep research on DSIP has produced inconsistent results. Some small studies reported improved sleep onset or quality in people with insomnia. Others found no meaningful effect on objective sleep architecture. The studies were mostly small, ran for short periods, and used varying preparations and routes. Nobody has run a modern, adequately powered, randomized, placebo-controlled trial with polysomnography as the endpoint.

Meanwhile, DSIP has also been studied for chronic pain and for opioid and alcohol withdrawal, mostly in Russian and Eastern European literature, with the same evidentiary limitations.

What happened in July 2026. The FDA's Pharmacy Compounding Advisory Committee reviewed seven peptides on July 23 and 24, 2026. Six were recommended for the 503A list. DSIP, listed as emideltide, was the only one voted down, by 7 to 6 with one abstention.

That vote is worth understanding for what it was. The same committee, in the same room, on the same days, recommended BPC-157, KPV, TB-500, MOTS-c, Semax, and epitalon. It was not a committee inclined to say no. It said no to this one.

Evidence by Outcome

Each claim below is rated using a GRADE-aligned five-tier system. Same molecule, different outcomes, different evidence.

Evidence at a glance

How we grade

SleepVery Low

Want to see how this compares to every other peptide? Browse the full evidence matrix, where every graded claim is grouped by outcome and sorted by certainty.

SleepVery Low certainty

Improves sleep quality or increases deep slow-wave sleep.

Population: Adults with insomnia and healthy adults

Why this rating

Human studies over nearly fifty years have been small, short, methodologically varied, and inconsistent, with some reporting benefit and others finding no effect on objective sleep architecture. No adequately powered, modern, randomized, placebo-controlled trial with polysomnography endpoints has been published. Sleep quality is also strongly placebo-responsive, so unblinded and self-reported evidence is close to uninformative. An FDA advisory committee reviewed this evidence in July 2026 and declined to recommend the compound.

GRADE downgrade factors applied

Inconsistency: Heterogeneous results across studies that cannot be explained, or pending replication.
Imprecision: Wide confidence intervals or small sample size, the estimate could be substantially different.
Risk of bias: Methodological flaws in the studies (e.g. lack of blinding, allocation concealment, high attrition).

Supporting studies

Human DSIP sleep studiesRandomized Controlled Trial
Inconsistent results across small trials, with no replication under modern standards.

Reviewed 2026-08-24· Designing Longevity EditorialHow we grade

Potential Benefits

Nearly fifty years of research existence, so it is not a compound that appeared last year with no history
Some small human studies reported improved sleep onset and quality in people with insomnia
Reported effects on cortisol rhythm normalization, which would be relevant to stress-related sleep problems
Generally reported as well tolerated in the studies conducted, with a mild side effect profile
Also investigated for chronic pain and withdrawal syndromes, with some positive reports

Risks & Considerations

Human sleep studies are small, inconsistent, and have not been replicated under modern standards
No clearly identified receptor or agreed mechanism after nearly fifty years of study
The only peptide an FDA advisory committee voted against in July 2026, in a session that approved six others
Placed in FDA 503A Category 2, and not recommended for removal
Nothing approved anywhere, so all supply is unregulated with unverified identity and purity
Sleep quality is highly placebo-responsive, and almost none of the supporting evidence is properly blinded
Real insomnia has effective treatments, and cognitive behavioral therapy for insomnia outperforms most drugs long-term

Dosing Information

There is no established dose. Studies used varying preparations and routes, and community protocols do not correspond closely to any of them.

•Community protocols commonly suggest 100 to 500mcg subcutaneously before bed
•Historical studies used intravenous and intranasal administration as well as subcutaneous
•Reported effects are described as inconsistent night to night even by people who use it
•No dose-response relationship has been established in humans
•We are not publishing a protocol for a compound with this level of evidentiary uncertainty

Need to mix this from a vial?

Use our reconstitution calculator to get the exact insulin syringe units to draw.

Practical Tips

1For chronic insomnia, cognitive behavioral therapy for insomnia has the strongest long-term evidence of anything, including prescription drugs
2Get the basics right first: consistent wake time, morning light, no alcohol near bedtime, cool dark room. These outperform most sleep supplements
3If you try DSIP, track it with a wearable or a sleep diary rather than relying on how rested you feel. Sleep perception is unreliable
4The July 2026 advisory vote is a meaningful signal. A committee willing to recommend six other peptides declined this one
5If sleep problems are persistent, get evaluated for sleep apnea before experimenting. It is common, treatable, and frequently missed

Key Research

Isolation of delta sleep-inducing peptide

Original discovery, Schoenenberger and Monnier, 1977

A nonapeptide was isolated from the blood of rabbits during electrically induced sleep and reported to increase delta wave sleep when transferred to other animals.

Human DSIP sleep studies

Various small trials

Small human studies produced inconsistent results. Some reported improved sleep onset and quality in insomnia; others found no meaningful effect on objective sleep architecture. No adequately powered modern trial with polysomnography endpoints has been published.

FDA Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026

FDA advisory committee proceedings, 2026

Emideltide (DSIP) was voted down 7 to 6 with one abstention, the only one of seven peptides reviewed that the committee declined to recommend for the 503A bulk drug substances list.

View Study

Want to learn more?

Explore related content and talk to a healthcare provider.

Browse All Treatments Find Your Goal

Always consult a healthcare provider before starting any treatment.This treatment has limited human evidence.

Frequently Asked Questions

Does DSIP actually improve sleep?

The evidence does not support a confident yes. Human studies over nearly fifty years have been small, short, and inconsistent, with some reporting improved sleep onset and others finding no effect on objective sleep architecture. No adequately powered modern trial with proper sleep measurement has been published. Sleep is also one of the most placebo-responsive things you can measure, which makes the unblinded reports particularly hard to trust.

Why is it called delta sleep-inducing peptide?

Because of what its discoverers hoped it did. In 1977, Swiss researchers electrically induced sleep in rabbits, isolated a peptide from their blood, and reported that transferring it to other animals increased delta wave sleep. They named it after that effect. The name has proven far more durable than the evidence, which is a useful thing to remember whenever a compound is named after its intended benefit.

What happened at the FDA meeting in July 2026?

The FDA's Pharmacy Compounding Advisory Committee reviewed seven peptides on July 23 and 24, 2026 and recommended six of them for the 503A bulk substances list: BPC-157, KPV, TB-500, MOTS-c, Semax, and epitalon. DSIP, listed as emideltide, was the only one voted down, 7 to 6 with one abstention. That the same committee said yes to six others makes the rejection more meaningful, not less.

Is DSIP safe?

The studies conducted have generally reported it as well tolerated, and there is no notable safety scandal attached to it. That said, "no reported harm in small short studies" is a weak safety claim, and there is no long-term human safety data. DSIP is also in FDA Category 2, which is where the agency puts substances with identified concerns.

What should I use for sleep instead?

Cognitive behavioral therapy for insomnia has the strongest long-term evidence of any intervention, including prescription sleep drugs, and its benefits persist after treatment ends. Beyond that, the unglamorous basics do more than most supplements: a consistent wake time, morning light exposure, no alcohol close to bedtime, and a cool dark room. If sleep problems persist, get screened for sleep apnea, which is common and frequently missed.

Why do people still sell DSIP?

Because it has a memorable name that states a benefit, a genuine 1977 discovery paper to point at, and nearly five decades of accumulated mentions that look like a body of evidence until you read them. None of that is the same as a trial showing it works.

New to Peptides?

Learn the basics of peptide therapy, how to inject safely, and what to look for in quality sources.

What Are Peptides? Peptide Safety Guide

Related Goals

The Energy Guide The Sharper Mind Guide

Related Peptides

SelankAnxiolytic Peptide (tuftsin analog)

EpithalonPineal Tetrapeptide